Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-FAPI-RGD
- Development stage
- Phase 2
- Lead developer
- Yantai Lannacheng Biotechnology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
68Ga-FAPI-RGD is a dual-receptor targeting PET radiotracer that binds to both fibroblast activation protein (FAP) and integrin αvβ3. This heterodimeric radiotracer combines a fibroblast activation protein inhibitor (FAPI) with an Arg-Gly-Asp (RGD) peptide, radiolabeled with gallium-68. It demonstrates high specificity and rapid internalization into target cells, with improved tumor uptake and tumor-to-background ratio compared to conventional 18F-FDG PET/CT. The effective dose from 68Ga-FAPI-RGD PET/CT is approximately 1.01 × 10^-2 mSv/MBq, with the thyroid receiving the highest effective dose followed by the urinary bladder wall, liver, and lungs.
- Other names
- Gallium 68-labeled fibroblast activation protein inhibitor-RGDGallium68-labeled fibroblast activation protein inhibitor-RGDGallium-68-labeled fibroblast activation protein inhibitor-RGD
02
Targets
FAP (Fibroblast activation protein alpha)αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on 68Ga-FAPI-RGD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-FAPI-RGD.